Influenza Virus-Like Particles as Pandemic Vaccines
Influenza Virus-Like Particles as Pandemic Vaccines
复制标题
DOI：
10.1007/978-3-540-92165-3_14
复制
发表时间：
2009-01-01
期刊：
影响因子：
--
通讯作者：
Compans, R. W.
中科院分区：
文献类型：
--
作者：
Kang, S. M.;Pushko, P.;Compans, R. W.
迫切需要开发针对新出现的致病性禽流感病毒的疫苗接种新方法，作为大流行防备的优先事项。流感病毒样颗粒(VLP)已被建议和开发为新一代非基于鸡蛋的细胞培养衍生疫苗，用于预防流感感染。流感VLP是通过将结构蛋白整合到由血凝素(HA)、神经氨酸酶(NA)和M1蛋白组成的萌芽颗粒中的自组装过程形成的，可能包括额外的流感蛋白，如M2。接种流行性感冒疫苗的动物免受雷哈尔流感感染引起的发病率和死亡率的影响。流感VLP疫苗的保护机制与目前获得许可的流感疫苗相似，可诱导中和抗体和血凝抑制活性。目前的研究表明，流感VLP方法可能是开发大流行性流感病毒疫苗的一种有前途的替代方法。2007年7月启动了重组大流行样H5N1流感VLP疫苗的第一次人类临床试验(Bright等人，未发表)。
There is an urgent need to develop novel approaches for vaccination against emerging pathogenic avian influenza viruses as a priority for pandemic preparedness. Influenza virus-like particles (VLPs) have been suggested and developed as a new generation of non-egg-based cell culture-derived vaccine candidates against influenza infection. Influenza VLPs are formed by a self-assembly process incorporating structural proteins into budding particles composed of the hemagglutinin (HA), neuraminidase (NA) and M1 proteins, and may include additional influenza proteins such as M2. Animals vaccinated with VLPs were protected from morbidity and mortality resulting from lehal influenza infections. The protective mechanism of influenza VLP vaccines was similar to that of the currently licensed influenza vaccines inducing neutralizing antibodies and hemagglutination inhibition activities. Current studies demonstrate that influenza VLP approaches can be a promising alternative approach to developing a vaccine for pandemic influenza viruses. The first human clinical trial of a recombinant pandemic-like H5N1 influenza VLP vaccine was initiated in July 2007 (Bright et al., unpublished).